{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:04:54Z","timestamp":1760425494827},"reference-count":58,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.schres.2016.07.017","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T17:07:53Z","timestamp":1469552873000},"page":"231-238","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial"],"prefix":"10.1016","volume":"176","author":[{"given":"Mantana","family":"Kittipeerachon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warawat","family":"Chaichan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2016.07.017_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"3","key":"10.1016\/j.schres.2016.07.017_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2016.07.017_bb0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2016.07.017_bb0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0735-6757(02)42249-8","article-title":"Calming versus sedative effects of intramuscular olanzapine in agitated patients","volume":"21","author":"Battaglia","year":"2003","journal-title":"Am. J. Emerg. Med."},{"issue":"8 Suppl 11","key":"10.1016\/j.schres.2016.07.017_bb0025","first-page":"4","article-title":"The treatment of acute agitation in schizophrenia","volume":"12","author":"Battaglia","year":"2007","journal-title":"CNS Spectr."},{"issue":"7","key":"10.1016\/j.schres.2016.07.017_bb0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003088-200847070-00004","article-title":"Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia","volume":"47","author":"Boulton","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.schres.2016.07.017_bb0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia","volume":"59","author":"Breier","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2016.07.017_bb0040","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/schbul\/sbr104","article-title":"Psychopharmacology of aggression in schizophrenia","volume":"37","author":"Buckley","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2016.07.017_bb0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2016.07.017_bb0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/15622970802688051","article-title":"Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation","volume":"10","author":"Castle","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.07.017_bb0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hup.870","article-title":"An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia\/schizoaffective disorder","volume":"22","author":"Centorrino","year":"2007","journal-title":"Hum. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.pra.0000314317.79544.b4","article-title":"Evaluation of the use of the Positive and Negative Syndrome Scale-excited component as a criterion for administration of p.r.n. medication","volume":"14","author":"Chaichan","year":"2008","journal-title":"J. Psychiatr. Pract."},{"issue":"12","key":"10.1016\/j.schres.2016.07.017_bb0070","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.4088\/JCP.v68n1207","article-title":"Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety","volume":"68","author":"Citrome","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.07.017_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/TCRM.S31484","article-title":"Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents","volume":"9","author":"Citrome","year":"2013","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0080","first-page":"209","article-title":"Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room","volume":"145","author":"Damsa","year":"2008","journal-title":"Bull. Soc. Sci. Med. Grand Duche Luxemb."},{"key":"10.1016\/j.schres.2016.07.017_bb0085","series-title":"Zyprexa Full Prescribing Information, Revised 23 July 2015","author":"Eli Lilly and Company","year":"2015"},{"issue":"3","key":"10.1016\/j.schres.2016.07.017_bb0090","first-page":"151","article-title":"Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study","volume":"36","author":"Escobar","year":"2008","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.schres.2016.07.017_bb0095","first-page":"34","article-title":"Intramuscular aripiprazole for the treatment of agitation in schizophrenia and bipolar disorder: from clinical research to clinical practice","volume":"19","author":"Fagiolini","year":"2013","journal-title":"J. Psychopathol."},{"issue":"8","key":"10.1016\/j.schres.2016.07.017_bb0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/11591710-000000000-00000","article-title":"Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management","volume":"25","author":"Gugger","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2016.07.017_bb0105","series-title":"Clinical Global Impressions","first-page":"218","author":"Guy","year":"1976"},{"issue":"1","key":"10.1016\/j.schres.2016.07.017_bb0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4037\/ajcc1996.5.1.7","article-title":"Managing agitation in critically ill patients","volume":"5","author":"Harvey","year":"1996","journal-title":"Am. J. Crit. Care"},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.07.017_bb0120","doi-asserted-by":"crossref","first-page":"273060","DOI":"10.1155\/2014\/273060","article-title":"Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia","volume":"2014","author":"Khasawneh","year":"2014","journal-title":"Cardiol. Res. Pract."},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.07.017_bb0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0920-9964(03)00087-2","article-title":"An excitement subscale of the positive and negative syndrome scale","volume":"68","author":"Lindenmayer","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.07.017_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0091270003261901","article-title":"Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers","volume":"44","author":"Mallikaarjun","year":"2004","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2016.07.017_bb0140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ajem.2005.02.050","article-title":"Emergency management of agitation in schizophrenia","volume":"23","author":"Marco","year":"2005","journal-title":"Am. J. Emerg. Med."},{"issue":"6","key":"10.1016\/j.schres.2016.07.017_bb0145","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.0608e17","article-title":"Treatment of agitation in patients with schizophrenia","volume":"69","author":"Marder","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.07.017_bb0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4088\/JCP.08m04411gry","article-title":"Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation","volume":"71","author":"Marder","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.07.017_bb0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0893-133X(01)00365-7","article-title":"Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia","volume":"26","author":"Meehan","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2016.07.017_bb0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-9-18","article-title":"Validation of the excited component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room","volume":"9","author":"Montoya","year":"2011","journal-title":"Health Qual. Life Outcomes"},{"issue":"8","key":"10.1016\/j.schres.2016.07.017_bb0165","first-page":"46","article-title":"Clinical challenges in the pharmacologic management of agitation","volume":"17","author":"Ng","year":"2010","journal-title":"Prim. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.07.017_bb0170","first-page":"646","article-title":"The Thai version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia: criterion validity and interrater reliability","volume":"83","author":"Nilchaikovit","year":"2000","journal-title":"J. Med. Assoc. Thail."},{"issue":"10 Suppl 17","key":"10.1016\/j.schres.2016.07.017_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1092852900026286","article-title":"Managing the acutely agitated and psychotic patient","volume":"12","author":"Nordstrom","year":"2007","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2016.07.017_bb0190","series-title":"Abilify Full Prescribing Information, Revised December 2014","author":"Otsuka Pharmaceutical","year":"2014"},{"issue":"3","key":"10.1016\/j.schres.2016.07.017_bb0180","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"4","key":"10.1016\/j.schres.2016.07.017_bb0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eurpsy.2010.04.005","article-title":"A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania","volume":"27","author":"Perrin","year":"2012","journal-title":"Eur. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2016.07.017_bb0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.eurpsy.2006.03.005","article-title":"A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients","volume":"21","author":"San","year":"2006","journal-title":"Eur. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.07.017_bb0200","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00023210-200822040-00005","article-title":"Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder","volume":"22","author":"Sanford","year":"2008","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.schres.2016.07.017_bb0205","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4088\/JCP.v69n1204","article-title":"A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation","volume":"69","author":"Satterthwaite","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.07.017_bb0210","series-title":"Manual of Clinical Psychopharmacology","author":"Schatzberg","year":"2007"},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1192\/apt.bp.109.007310","article-title":"Management of acute agitation in psychosis: an evidence-based approach in the USA","volume":"17","author":"Schleifer","year":"2011","journal-title":"Adv. Psychiatr. Treat."},{"issue":"8","key":"10.1016\/j.schres.2016.07.017_bb0220","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2016.07.017_bb0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2016.07.017_bb0230","article-title":"Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia","volume":"10","author":"Tardy","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.schres.2016.07.017_bb0235","first-page":"401","article-title":"Antipsychotic prescribing\u2014time to review practice","volume":"26","author":"Taylor","year":"2002","journal-title":"Psychiatrist"},{"key":"10.1016\/j.schres.2016.07.017_bb0240","series-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2009"},{"issue":"1","key":"10.1016\/j.schres.2016.07.017_bb0245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.07.017_bb0250","author":"U.S. Food and Drug Administration Psychopharmacological Drugs Advisory Committee"},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0255","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00023210-200519020-00005","article-title":"Intramuscular olanzapine: a review of its use in the management of acute agitation","volume":"19","author":"Wagstaff","year":"2005","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.schres.2016.07.017_bb0260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5811\/westjem.2011.9.6866","article-title":"The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup","volume":"13","author":"Wilson","year":"2012","journal-title":"West J. Emerg. Med."},{"issue":"6","key":"10.1016\/j.schres.2016.07.017_bb0265","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jemermed.2014.01.017","article-title":"Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department","volume":"46","author":"Wilson","year":"2014","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.schres.2016.07.017_bb0270","series-title":"Guidelines for ATC Classification and DDD Assignment 2015, Oslo","year":"2014"},{"issue":"7","key":"10.1016\/j.schres.2016.07.017_bb0280","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia","volume":"158","author":"Wright","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2016.07.017_bb0285","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/070674370304801102","article-title":"Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24hours of treatment","volume":"48","author":"Wright","year":"2003","journal-title":"Can. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2016.07.017_bb0290","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5811\/westjem.2015.12.28763","article-title":"Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting","volume":"17","author":"Zeller","year":"2016","journal-title":"West J. Emerg. Med."},{"issue":"3","key":"10.1016\/j.schres.2016.07.017_bb0295","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00023210-200822030-00002","article-title":"Pharmacological control of acute agitation: focus on intramuscular preparations","volume":"22","author":"Zimbroff","year":"2008","journal-title":"CNS Drugs"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416303334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416303334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T10:06:26Z","timestamp":1600941986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416303334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":58,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0920996416303334"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.07.017","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}